Please assess the completion status of the following clinical trial:

Trial Title: Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with moderate to severe early rheumatoid arthritis (\< 2 years) who are methotrexate and biologic disease modifying antirheumatic drug naive.~Exclusion Criteria:~* Pregnant or lactating patients;~* Patients with renal or hepatic impairment or other severe or progressing disease;~* Patients with contraindication to magnetic resonance imaging with gadolinium contrast.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (CP 690,550) 10 mg BID plus MTX (Type: EXPERIMENTAL): None
- Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX (Type: EXPERIMENTAL): None
- Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).